Published in Food and Drug Law Weekly, November 3rd, 2006
Onconase, first in class in the ribonuclease family, is currently the subject of a randomized phase III clinical trial in combination with doxorubicin as a potential treatment for patients with unresectable malignant mesothelioma (UMM).
The company will submit the chemistry, manufacturing and controls (CMC) section of the NDA after completion of a review by external regulatory consultants. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.